GlassScriptPhysician profile
Ann Bich Nguyen
NPI 1629208988
$4,805.38
in general payments reported to CMS, 2019-2025
23 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $340 · 2021: $624 · 2022: $620 · 2023: $513 · 2024: $961 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.14 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,394.71 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $306.75 | 2019 | |
| Abiomed | $289.22 | 2023 | Impella |
| Cvrx, INC. | $258.75 | 2021-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $246.33 | 2021-2024 | Lifevest |
| Medtronic, INC. | $203.54 | 2021-2024 | Selectsecure, Cobalt Dr Mri Surescan |
| Paragonix Technologies, INC. | $138.11 | 2024 | Liverguard, Lungguard, Baroguard |
| Itamar Medical INC | $130.36 | 2022 | |
| Boston Scientific Corporation | $121.14 | 2020 | |
| Novartis Pharmaceuticals Corporation | $118.70 | 2019-2025 | |
| Pfizer INC. | $99.51 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $92.16 | 2022-2024 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $75.81 | 2022-2025 | Camzyos |
| Amgen INC. | $68.97 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $54.41 | 2022-2023 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $46.14 | 2019 | |
| Zoll Circulation INC | $35.32 | 2021 | |
| Procyrion, INC. | $26.81 | 2022 | |
| Genzyme Corporation | $25.41 | 2024 | |
| Akcea Therapeutics, INC. | $21.39 | 2019 | |
| Portola Pharmaceuticals, LLC | $18.71 | 2019 | |
| Atricure, INC. | $17.76 | 2025 | Atriclip Laa Exclusion System |
| Janssen Pharmaceuticals, INC | $15.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.